BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36135761)

  • 1. A Nutraceutical Formulation Containing Brown Algae Reduces Hepatic Lipid Accumulation by Modulating Lipid Metabolism and Inflammation in Experimental Models of NAFLD and NASH.
    Gabbia D; Roverso M; Zanotto I; Colognesi M; Sayaf K; Sarcognato S; Arcidiacono D; Zaramella A; Realdon S; Ferri N; Guido M; Russo FP; Bogialli S; Carrara M; De Martin S
    Mar Drugs; 2022 Sep; 20(9):. PubMed ID: 36135761
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gabbia D; Saponaro M; Sarcognato S; Guido M; Ferri N; Carrara M; De Martin S
    Mar Drugs; 2020 Jan; 18(1):. PubMed ID: 31963560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
    Ren T; Zhu J; Zhu L; Cheng M
    Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH.
    Gabbia D; Dall'Acqua S; Di Gangi IM; Bogialli S; Caputi V; Albertoni L; Marsilio I; Paccagnella N; Carrara M; Giron MC; De Martin S
    Mar Drugs; 2017 Feb; 15(2):. PubMed ID: 28212301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models.
    Miyashita T; Toyoda Y; Tsuneyama K; Fukami T; Nakajima M; Yokoi T
    J Toxicol Sci; 2012; 37(5):931-42. PubMed ID: 23038002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
    Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perilipin-2 Deletion Impairs Hepatic Lipid Accumulation by Interfering with Sterol Regulatory Element-binding Protein (SREBP) Activation and Altering the Hepatic Lipidome.
    Libby AE; Bales E; Orlicky DJ; McManaman JL
    J Biol Chem; 2016 Nov; 291(46):24231-24246. PubMed ID: 27679530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
    Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
    Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
    Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
    Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.
    Kwan HY; Niu X; Dai W; Tong T; Chao X; Su T; Chan CL; Lee KC; Fu X; Yi H; Yu H; Li T; Tse AK; Fong WF; Pan SY; Lu A; Yu ZL
    Sci Rep; 2015 Mar; 5():9114. PubMed ID: 25766252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
    Xu L; Kim JK; Bai Q; Zhang X; Kakiyama G; Min HK; Sanyal AJ; Pandak WM; Ren S
    Mol Pharmacol; 2013 Mar; 83(3):648-58. PubMed ID: 23258548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
    Ma R; Zhan Y; Zhang Y; Wu L; Wang X; Guo M
    Drug Dev Res; 2022 May; 83(3):735-744. PubMed ID: 34927282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
    Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.